CanaryBio Reveals Global Phase 3 Clinical Trial Status at ASCO

[Asia Economy Reporter Jang Hyowon] Canaria Bio (CEO Nahanik) announced on the 25th that Sunil Gupta, Chief Medical Officer (CMO), will personally present the Phase 2 clinical trial results and the progress of the global Phase 3 clinical trial of the ovarian cancer immuno-oncology drug Oregovomab at the American Society of Clinical Oncology Annual Meeting (ASCO 2022) on June 4.

Oregovomab is a new drug that showed an encouraging result of progression-free survival (PFS) extended by 30 months to 42 months compared to the existing standard treatment in the Phase 2 clinical trial. It was also recommended as the most promising new drug among immuno-oncology agents targeting ovarian cancer by the oncology specialist site ‘OncoLive’.

Nahanik, CEO of Canaria Bio, stated, “Oregovomab is a cancer treatment vaccine administered only four times together with chemotherapy, and theoretically, it could become a drug that all ovarian cancer patients should use,” adding, “We are currently discussing strategic partnerships with global pharmaceutical companies.”

The global Phase 3 clinical trial of Oregovomab is being conducted at 130 sites in 14 countries under the clinical leadership of Dr. Angeles Secord (Duke University Cancer Institute, USA). The trial is ongoing at 67 sites in the United States, as well as in Europe, South America, and Asia. In Korea, Seoul National University Hospital, Bundang Seoul National University Hospital, Yonsei University Severance Hospital, Seoul St. Mary’s Hospital, Korea University Anam Hospital, Seoul Asan Hospital, and the National Cancer Center are participating in the global Phase 3 clinical trial. The trial aims to recruit a total of 602 patients and has completed enrollment of 270 patients as of the end of May.

The company plans to complete patient recruitment for the global Phase 3 clinical trial by the end of 2022 and announce interim results in 2023. Information about the clinical trial can be found in the U.S. clinical information system under NCT number 04498117.

This content was produced with the assistance of AI translation services.